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Abstract: Low vision devices in the past have been mainly extraocular. There are now four 
new devices in different stages of development and implementation that are currently available. 
Three of them, the Implantable Miniature Telescope (IMT, VisionCare Ophthalmic Technolo-
gies, Saratoga, CA), Intraocular Lens for Visually Impaired People (IOL-VIP, IOL-VIP System, 
Soleko, Pontecorvo, Italy), and Lipschitz Mirror Implant (LMI, Optolight Vision Technology, 
Herzlia, Israel) are implanted into the anterior segment while the Argus II (Second Sight Medi-
cal Products, Sylmar, CA) is implanted into the posterior segment. The goal of these devices 
is to increase the patient quality of life which has been measured by Visual   Functioning Ques-
tionnaire (VFQ) scales. The IMT is the only device that has been shown to increase the VFQ 
score by seven points at 6 months compared to baseline. It is the only FDA-approved device in 
the US while the Argus has been approved in Europe. Each of these prosthetics has potential 
benefits for patients.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in adults 
over the age of 65 years.1 As the life expectancy in civilized countries increases, 
the growing incidence of AMD presents an important public health concern.2 Dry 
AMD accounts for approximately 90% of all AMD cases and is characterized by 
the accumulation of deposits in Bruch’s membrane and pigmentary changes in the 
retinal pigment epithelium. Wet AMD is the more severe form, accounts for 10% of 
all AMD cases and is caused by retinal tissue invasion of new blood vessels,   choroidal 
neovascularization (CNV).3 The macula is the region of the retina that provides central 
vision. CNV leads to inflammation, edema and scarring, with loss of structure and 
function of the macula.
Treatment for dry AMD has primarily focused on preventing at-risk patients 
from progressing to the wet form. Treatment for wet AMD has been limited.4 The 
age-related changes that cause CNV are not completely understood, but vascular 
endothelial growth factor (VEGF) has been identified as an important factor   promoting 
neovascularization.5 Treatment for AMD includes administration of anti-VEGF. 
Ranibizumab (Lucentis®, Genentech, San Francisco, CA) was approved by the Food 
and Drug Administration for the treatment of all angiographic subtypes of subfoveal 
neovascular age-related macular degeneration in 2006.6 Ranibizumab has been shown 
to improve visual acuity by three lines in 30%–40% of patients with monthly dosing.7 
Bevacizumab has been shown to be equivalent to Ranibizumab with monthly dosing.8 
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However, anti-VEGF treatment does not work for everyone. 
Despite treatment some patients still progress, especially 
those with geographic atrophy.9
Advanced AMD, a common pathway of both the dry 
and wet form, is the end-stage with presentation of   bilateral, 
untreatable macular scars causing central scotomata 
(blind spots). These blind spots result in significant visual 
  impairment that limits a patient’s daily activities requiring 
good central vision, such as self-care, reading, recognizing 
facial features, driving, watching television, and other social 
activities. Advanced AMD is also associated with legal 
blindness, increased risk of depression, increased levels of 
dependency, increased risk of accidents, and a significant 
decrease in quality of life (QOL).10–12 Currently, there are 
no medical treatments for end-stage AMD.
Extraocular low vision aids
Visual rehabilitation with low vision magnifiers has been 
the mainstay of treatment for patients with advanced dry 
macular degeneration, diabetic retinopathy, and retinal vein 
occlusions.13 Patients with these diseases have a decreased 
ability to carry out activities of daily living including reading, 
writing, and grooming which in turn causes a deterioration 
in their QOL.
Currently there are many nonsurgical options for visual 
rehabilitation, some examples are: hand/stand magnifiers, 
spectacles, hand held telescopes, closed circuit televisions, 
and high plus spectacles in conjunction with high minus con-
tact lenses to create a telescopic effect. Although these tools 
maybe effective for correcting overall visual   functioning, 
there are several limitations especially when correcting 
distance and near acuity.
In order to obtain effective magnification, patients have 
to bring objects closer to the eye to increase the angle of 
resolution. In addition to moving objects closer, these devices 
are cumbersome to use, they are cosmetically burdensome, 
and most of all, these external devices restrict effective field 
of view. The majority of these magnifying devices have a 
restricted field-of-view and have to be manually scanned 
across the text, magnifying only a small portion at a time. 
In all cases, the scanning is slow and limits the usefulness of 
the device. Patients are also required to use head movements 
or hand movements more often than using natural eye move-
ments to scan which results in vestibular-ocular conflict and 
motion sickness. Furthermore, patients afflicted with arthritis, 
Parkinson’s disease or other neuromuscular disorders, or 
dementia, among others, will have difficulty maneuvering 
these devices in a useful way. Despite all this, patients are 
willing to try anything for a chance of better vision, no matter 
how difficult and burdensome these devices may be.
In addition to the hand-held and stand magnifiers, 
  spectacle-mounted telescopes are a great alternative. They 
not only provide good magnification but also allow using 
eye movements to a limited field of fixation. The draw-
back of these devices is that they are very dependent on 
vertex distance. For example, Nguyen et al reported fields 
from 5° to 11° for varying telescopes set at 10 mm from 
the cornea.14 Bailey reported for a 3.0× spectacle-mounted 
telescope a field-of-view of 11° for the Galilean design and 
14° for the Keplerian design.15 With such a narrow field, 
navigation in the visual environment is difficult and may be 
dangerous. Patients are forced to use head scanning to cover 
a wider angle through the telescope.
The limitations on the field-of-fixation are even more 
severe with the combined IOL/spectacle telescopic (or   contact 
lens/spectacle) system. With this device, the field-of-fixation 
was computed to be only between 1° and 5° depending on 
lens design and vertex distance.14
For distance vision, the choice is limited to telescopes, 
headset devices, and closed circuit televisions, all of which 
have a high cost/benefit ratio and generally lead to patient 
frustration and abandoning of the device.15 However, for 
many years, low-vision magnifiers have provided patients 
with an opportunity to enhance their existing vision with 
the goal to improving their QOL. Furthermore, this was an 
attractive option as a noninvasive way for patients to avoid 
surgery and have the opportunity to gain vision and until 
recently, this was the only option available. Current research 
and development are aiming at ways to utilize the natural 
eye and visual system to augment the parts of the patient’s 
architecture with normal function. The future of low magni-
fiers now includes devices that can be implanted in the eye, 
improving the field of magnification and ease of use.
Intraocular implants
Intraocular implants are an attractive and intuitive way to 
circumvent many of the problems faced in extraocular visual 
aids. With the addition of plus lenses, these devices may 
be used for near activities as well. There are currently four 
different types of intraocular implant available for use and 
these include both devices placed in the anterior segment as 
well as the posterior segments of the eye. We will review three 
devices for the anterior segment, the Implantable Miniature 
Telescope (IMT by Dr Isaac Lipshitz, VisionCare Ophthalmic 
Technologies, Saratoga, CA),4,13,17–21 the IOL-VIP system 
(IOL-VIP System, Soleko, Pontecorvo, Italy),16 and the 
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Lipschitz Mirror Implant (LMI, Optolight Vision Technology, 
Herzlia, Israel),22 and one device for the posterior segment, 
the Argus II retinal implant by Second Sight (Second Sight 
Medical Products, Sylmar, CA).23 There are many advantages 
to such implants as compared to magnifiers and spectacles as 
described previously. One very important consideration is eye 
movement control with the field of view. Because scanning eye 
movements are necessary for normal functioning, it is easy to 
imagine why magnifiers or spectacles could impede the best 
sight as the patient would have to be constantly moving the 
lens to a new point in space as well as adjust to the interaction 
of the ring scotoma caused by such devices. With the device 
implanted within the eye, many of these barriers are elimi-
nated.   Furthermore, the effective field-of-fixation varies based 
on design where a Galilean design affords approximated 6° for 
the 3.0× design and 10° for the Keplerian design. Furthermore, 
with the combined IOL/spectacle device, the computed field 
is between 1° and 5°, dramatically less than the 20° for the 
3× and 24° with the 2.2× IMT devices.
A second important characteristic of implantable devices 
is the improvement in head motion and vestibular effects. 
Whenever using a head-mounted magnifying device, there 
are disruptions in image stability and image direction. 
Furthermore, with the vestibular ocular reflex (VOR), eye 
movements are programmed to occur one-to-one with 
head movement. However, when using a magnifier with 
3.0×   magnification for example, an eye movement three times 
as large as head rotation is required which is very difficult if 
not impossible to achieve by VOR adaptation. This is further 
complicated when using a telescope monocularly as there is 
a different demand between the two eyes. This problem is 
resolved by the different implantable systems since a given 
head movement requires a compensatory eye movement of 
the same magnitude.
A third advantage of intraocular devices is the improve-
ment in monocular depth perception. Any device that is 
using a monocular magnification will have to overcome the 
intrinsic problem of altered depth perception because of 
the lack of binocular disparity and stereovision. Oftentimes 
the use of monocular cues such as interposition, relative 
sizes of known objects, linear perspective, foreshortening 
and aerial perspective, can provide a useful sense of depth 
perception. Another phenomenon important in monocular 
depth perception is motion parallax, where objects closer 
to the eye appear to move faster than objects moving at the 
same speed at a farther distance. This same phenomenon 
can be used to judge depth in static objects by the lateral 
movement of the eye or moving the head so that a closer 
object will move faster on the retina and cover a larger area 
than a farther object. This cannot usually be accomplished 
by rotational eye movements because the rotational axis 
is close to the nodal point however the nodal point of the 
eye is shifted anteriorly by a telescope system and thus can 
generate enough parallax to provide fine depth perception 
for near tasks.
Anterior segment devices
The concept of using a minus and plus lens as a magnifier for 
retinal image enlargement has been used for visual rehabili-
tation in low-vision patients for many years. Implants like 
the IMT and the IOL-VIP system have been shown to have 
promising results.
IMT device
The IMT is a visual prosthetic device that provides the eye 
with an enlarged retinal image of the central visual field with 
the goal of improving central vision in one eye of patients 
with moderate to profound visual impairment.13 Earlier 
generations of the IMT have been reported.19 It incorporates 
ultra-precision wide-angle micro-optics that, together with 
the cornea, functions as a fixed focus telephoto system. The 
housing measures 3.6 mm in diameter and 4.4 mm in length 
in a polymethylmethacrylate carrier with haptics measuring 
13.5 mm in diameter designed to be implanted “in the bag” 
(Figure 1). In doing so, it generates an image over 55° of 
the retina, versus the 5° focused by the natural crystalline 
lens. Furthermore, this can be done while still minimizing 
the patient’s scotoma and retaining a   relatively wide 20°–24° 
field of view. The device has undergone Phase II and III   
Figure 1 Implantable Miniature Telescope (IMT by Dr Isaaz Lipshitz; VisionCare 
Ophthalmic Technologies,Saratoga, CA, USA).18
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  testing and has very promising results and was been approved 
by the Food and Drug Administration in July of 2010. Most 
patients enrolled in the Phase III studies have had a baseline 
mean composite score of 44/100 on the National Eye Institute 
Visual Functioning Questionnaire [NEIVFQ]-25. Most had 
disciform scarring due to CNV or geographic atrophy and 
the mean endothelial cell count was 2492 cells/mm2. Patients 
excluded were those with active CNV or treatment within 
the preceding 6 months, history of intraocular or corneal 
surgery, pathology that compromises peripheral vision in the 
fellow eye, endothelial cell density ,1600 cells/mm2, anterior 
chamber depth ,2.5 mm, myopia or hyperopia .6.0 D, 
glaucoma, or other retinal or optic nerve pathology.4
This device has the most peer-reviewed literature 
  discussing its patient selection, use and outcomes, and 
is the only telescope system that is FDA approved. A 
  specific   surgical procedure has been described to minimize 
  endothelial cell loss and morbidity associated with the 
implantation.   Typically, the procedure is done beginning 
with a retrobulbar block and the lens is removed using 
extracapsular cataract extraction with phacoemulsification. 
The size of the device requires a 12-mm partial thickness 
limbal incision and a   capsulorhexis of at least 7 mm and is 
closed with 10.0 nylon sutures. After the ophthalmic vis-
coelastic device (OVD) is removed, the pupil is constricted 
using an intraocular miotic and a peripheral iridectomy is 
performed.18 Because of the size of the device relative to 
standard intraocular lenses, the corneal endothelial health 
raises a significant concern. There has been a documented 
decline of approximately 20% at 3 months postoperatively. 
However, there is a low rate of additional endothelial cell 
loss, leading to the assumption that most damage occurs at 
the time of surgery and can be minimized by careful atten-
tion to surgical technique.21
A potential risk related to the procedure is corneal 
endothelial cell loss that can affect overall corneal health. 
Longer-term FDA safety data collected for over 4 years 
follow-up showed 5/217 (2.3%) of patients required a corneal 
transplant.24 Mean endothelial cell loss was 25% at 1-year 
postoperative, and stabilized from 1 through 2 years, with 
2.4% mean cell loss occurring in that period. There was no 
significant change in coefficient of variation or percentage 
of hexagonal endothelial cells from within 6 months to 2 
years after surgery. The most common complication was 
inflammatory deposits.25
The procedure is very safe and has very few anterior 
  segment complications in long term follow-up. This has 
led investigators to achieve results comparable to   current 
  standards of care in rates of keratopathy and   postoperative 
  complications, keeping in mind the relatively short 
follow-up.
The IMT has had very promising success in clinical 
trials. The primary efficacy end-point required by the 
FDA protocol was to achieve greater than or equal to 50% 
of patients gaining two or more lines of either near or 
distance visual acuity at 12 months. At the 12-month mark, 
this end-point was achieved in 90% of patients with 67% 
gaining three or more lines in best-corrected distance visual 
acuity. A   secondary end-point was improvement in QOL 
as measured by the NEIVFQ-25 which showed mean NEI 
VFQ-25 scores at 1 year improved by more than 7 points 
from baseline (P , 0.01) on 7 of 8 relevant subscales. This 
telescope has the potential to afford a major advance in the 
vision and QOL to many patients with moderate to profound 
vision loss without the cumbersome extraocular visual aids 
or social stigma associated with hardware on and around 
the eye.4
The IOL-VIP system
The IOL-Vip System is a Lenspecial project from Soleko. It 
uses two IOLs that act as a Galilean telescope, a high minus 
IOL in the bag, and a high plus anterior chamber intraocular 
lens (ACIOL) (Figure 2). A clinical trial using the IOL-VIP 
system was carried out in 40 eyes of 35 patients.17 Extensive 
preoperative   training and   software recognition programs 
were used to select these 35 patients. All the surgeries were 
performed at an   ambulatory surgery center (ASC), and 
patients underwent a laser PI before placement of the ACIOL 
Figure 2 Intraocular Lens for Visually Impaired People (IOL-VIP System; Soleko, 
Pontecorvo, Italy).16
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(either preoperative or intraoperative). In addition every 
patient had a preoperative endothelial cell count.
The study did not find a difference in complication or 
endothelial cell count when compared to the conventional 
phacoemulsification procedure. There were some complica-
tions including elevated IOP from pupillary block, anterior 
capsule fibrosis, and posterior capsular opacification, all 
of which were treated using the ND YAG laser. All of the 
patients completed the postoperative 3-month rehabilitation 
program. They found that all the 40 eyes (both groups – the 
severely low vision and the mild-low vision) had improve-
ment in their BCVA postoperatively, however the mild-low 
vision group seemed to have a better outcome.
The IOL-VIP system allows patients to retain their periph-
eral vision. This IOL-VIP implant has been used in patients 
with central scotomas and maculopathy since 2002 in Spain 
and in the UK.16
Although this is an excellent alternative to the conven-
tional external low-vision aids there might be some additional 
factors to take into consideration. Using two lenses, espe-
cially an ACIOL, can have a crowding effect leading to 
glaucoma or angle closure especially in hyperopic patients. 
Furthermore the concave and convex lenses that provide 
magnification are at the lens-aqueous interface, as these 
lenses are surrounded by aqueous. Thus, the magnification 
is limited to 1.3×.15 In addition, the pre- and postoperative 
visual rehabilitation takes months, which could be inconve-
nient for patients.16
Overall, the IOL-VIP system seems to have a favorable 
outcome on the patients that currently have these implants 
and the results seem promising.
Intraocular mirror telescopic intraocular 
lens (Lipshitz Mirror implant or LMI)
The Lipshitz implant is a modified conventional IOL that 
follows the Cassegrain telescopic configuration, using two 
miniature mirrors.22 The IOL has a dual optical system 
by which light passing through the positive and negative 
lenses ends up being magnified (Figure 3). The LMI implant 
has been designed to give the patient 2.5× central retinal 
magnification.22
A prospective, nonrandomized pilot clinical trial was 
conducted at Dr Agarwal’s Eye Research Center from June 
to December 2006. Six eyes of six patients were selected, 
with macular pathology and corrected VA ,20/200 whose 
vision improved with a 2.5× external telescope.
Postoperatively, patients were tested for changes in central 
VA, and were asked to complete a QOL questionnaire. The 
LMI implant was well tolerated in all the patients with no 
intra-operative complications. In addition, most patients 
reported an improvement in their central visual acuity 
and their QOL. Some patients complained of glare in the 
immediate postoperative period that seemed to be suppressed 
by the 6-month follow-up.22
There is also a new model of the mirror telescope called 
the OriLens and it is for pseudophakic patients. It is a sulcus 
fixated lens placed over an existing IOL. It is indicated for 
phakic and pseudophakic eyes and is only 1.25 mm thick. It 
is currently the only option for pseudophakic patients. The 
OriLens is CE certified and is used in Europe and other non-
FDA regulated markets.
Retinal implants
In contrast to using image magnification via optical devices 
to improve vision, a number of retinal-based prostheses are 
currently under investigation. These devices differ from the 
implantable prostheses in many ways. They are composed 
of highly complex integrated microchips and are offered 
to patients who are almost completely blind from retinal 
degenerations such as retinitis pigmentosa. The Argus II26,27 
epiretinal prosthesis was shown to improve performance in 
spatial motor tasks, and the subretinal Retina Implant28 (Retina 
Implant AG, Tubingen-Reutlingen, Germany) was shown to 
allow blind patients to recognize images and read letters. 
However, the latter retinal implant is not applicable at present 
in patients with age-related macular degeneration and thus 
will not be discussed in this review. The Argus II is a retinal 
prosthesis system that combines a digital camera built into 
a pair of glasses, which processes the images into electrical 
impulses and transmits these pulses to a transmitter that com-
municates with the retinal implant stimulating the nerve cells 
and taking advantage of an intact optic nerve and posterior 
visual pathway (Figure 4). Currently, the implant consists of 
an array of 60 electrodes on a 1 mm × 1 mm chip and can give 
subjects the ability to perceive shapes in contrast in relatively 
Figure  3  Lipshitz  Mirror  implant  (LMI;  Optolight  Vision  Technology,  Herzlia, 
Israel).22
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low resolution. Argus II recently received the CE mark and is 
now available for sale in Europe. The researchers at Second 
Sight are currently working on Argus III and IV which are 
projected to have as many as 1000 electrodes in an effort to 
gain facial recognition. Retinal implants provide another excit-
ing advance in the treatment of profound vision loss.
Discussion
When comparing anterior segment implants, the IMT has sig-
nificantly more peer-reviewed literature and clinical data than 
the IOL-VIP System or the Lipshitz Mirror IOL. The IOL-VIP 
system has been reviewed at one center with a relatively low 
number of eyes (n = 40). The magnification has been minimal 
(1.3×) and a prismatic effect has been reported.
The initial study of the LMI involved a low number of 
eyes (n = 6) and a short follow-up time (6 months) at only one 
center. In a study by Agarwal et al,22 the advantages of this 
implant over the IMT are discussed, which include preserva-
tion of peripheral vision, no significant loss of endothelial 
cells as a result of an easier procedure, and finally the ability 
to place bilateral implants in patients, unlike the IMT. How-
ever, some patients noted the glare from the mirrored IOLs 
to be bothersome, especially from a cosmetic standpoint in 
younger patients.
The IMT has been FDA-approved for the treatment 
of AMD. When compared to the other anterior segment 
implants, the number of IMT patients is significantly higher 
in the 1-year (n = 217) and 2-year (n = 174) follow-up reports. 
Patients involved in the IMT clinical trial are currently in 
long-term follow-up and are approaching 96-month (8-year) 
follow-up visits.
The QOL improvements with the IMT, as mentioned 
previously, are of particular note. The NEIVFQ is considered 
the gold standard QOL measure for ophthalmic interventions.   
A five-point improvement in the VFQ-25 score is considered 
clinically meaningful: the 1-year IMT follow-up showed a 
clinically meaningful increase in the VFQ-25 when compared 
to baseline. The 1- and 2-year follow-up articles on the IMT 
show that improved vision as a result of the telescope-eye best 
corrected visual acuity is responsible for increased QOL in study 
subjects. Furthermore, a recent study has shown the procedure 
to be cost-effective in terms of the utility gained by patients.29
Conclusion
Low-vision aids and intraocular implants are all designed to 
help patients improve their vision in end-stage age-related 
macular degeneration and by extension, QOL. We have 
shown that the current direction should logically trend toward 
smaller, less cumbersome, more efficient and effective 
devices for this increasing patient population. This can best 
be accomplished through intraocular implants. In addition, 
these devices with the addition of plus lenses, have the ability 
to be used for both distance and near.
The anterior segment implants have the advantage of 
utilizing a surgical skill that has already been honed by many 
ophthalmologists in the placement of posterior chamber IOLs 
after cataract surgery. At this time, the only FDA-approved 
implant is the implantable miniature telescope (IMT) device 
for the US and the Argus II posterior segment implant for 
the European Union. These are promising achievements and 
a welcome addition to the existing armamentarium of low-
vision devices. These devices help to increase the QOL in 
low-vision patients until a preventative intervention or cure 
is discovered.
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